India’s first indigenous Dengue vaccine begins pivotal phase 3 Trial
In a landmark development for public health in India, the Indian Council of Medical Research (ICMR) and Panacea Biotec have commenced the Phase 3 clinical trial of DengiAll, the country’s first indigenous tetravalent dengue vaccine. This pivotal trial will assess the vaccine’s efficacy in preventing dengue, a disease that poses a significant health threat in…